163 related articles for article (PubMed ID: 33219385)
21. Evaluation of a Clinically Relevant Drug-Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity.
Ning C; Su S; Li J; Kong D; Cai H; Qin Z; Xing H; Chen X; He J
Front Pharmacol; 2021; 12():715577. PubMed ID: 34646133
[No Abstract] [Full Text] [Related]
22. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
23. Proteomics-Informed Prediction of Rosuvastatin Plasma Profiles in Patients With a Wide Range of Body Weight.
Wegler C; Prieto Garcia L; Klinting S; Robertsen I; Wiśniewski JR; Hjelmesaeth J; Åsberg A; Jansson-Löfmark R; Andersson TB; Artursson P
Clin Pharmacol Ther; 2021 Mar; 109(3):762-771. PubMed ID: 32970864
[TBL] [Abstract][Full Text] [Related]
24. Advancing Estimation of Hepatobiliary Clearances in Physiologically Based Pharmacokinetic Models of Rosuvastatin Using Human Hepatic Concentrations.
Wang L; Zhu Z; Tran D; Seo SK; Pan X
Pharm Res; 2021 Dec; 38(12):2035-2046. PubMed ID: 34862570
[TBL] [Abstract][Full Text] [Related]
25. Predictive Performance of Next Generation Physiologically Based Kinetic (PBK) Model Predictions in Rats Based on In Vitro and In Silico Input Data.
Punt A; Louisse J; Pinckaers N; Fabian E; van Ravenzwaay B
Toxicol Sci; 2022 Feb; 186(1):18-28. PubMed ID: 34927682
[TBL] [Abstract][Full Text] [Related]
26. Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling.
Ball K; Jamier T; Parmentier Y; Denizot C; Mallier A; Chenel M
Eur J Pharm Sci; 2017 Aug; 106():122-132. PubMed ID: 28552429
[TBL] [Abstract][Full Text] [Related]
27. Does the Systemic Plasma Profile Inform the Liver Profile? Analysis Using a Physiologically Based Pharmacokinetic Model and Individual Compounds.
Li R; Maurer TS; Sweeney K; Barton HA
AAPS J; 2016 May; 18(3):746-56. PubMed ID: 26951483
[TBL] [Abstract][Full Text] [Related]
28. Predictive performance of next generation human physiologically based kinetic (PBK) models based on in vitro and in silico input data.
Punt A; Louisse J; Beekmann K; Pinckaers N; Fabian E; Van Ravenzwaay B; Carmichael PL; Sorrell I; Moxon TE
ALTEX; 2022; 39(2):221–234. PubMed ID: 35064272
[TBL] [Abstract][Full Text] [Related]
29. Transport Kinetics, Selective Inhibition, and Successful Prediction of In Vivo Inhibition of Rat Hepatic Organic Anion Transporting Polypeptides.
Ishida K; Ullah M; Tóth B; Juhasz V; Unadkat JD
Drug Metab Dispos; 2018 Sep; 46(9):1251-1258. PubMed ID: 29891589
[TBL] [Abstract][Full Text] [Related]
30. Supplemental Analysis of the Prediction of Hepatic Clearance of Binary Mixtures of Bisphenol A and Naproxen Determined in an Isolated Perfused Rat Liver Model to Promote the Understanding of Potential Albumin-Facilitated Hepatic Uptake Mechanism.
Poulin P; Bteich M; Haddad S
J Pharm Sci; 2017 Nov; 106(11):3207-3214. PubMed ID: 28823401
[TBL] [Abstract][Full Text] [Related]
31. Biopharmaceutic
Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
[TBL] [Abstract][Full Text] [Related]
32. Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?
Gomez-Mantilla JD; Huang F; Peters SA
Clin Pharmacokinet; 2023 Mar; 62(3):457-480. PubMed ID: 36752991
[TBL] [Abstract][Full Text] [Related]
33. Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Chen Y; Samineni D; Mukadam S; Wong H; Shen BQ; Lu D; Girish S; Hop C; Jin JY; Li C
Clin Pharmacokinet; 2015 Jan; 54(1):81-93. PubMed ID: 25223698
[TBL] [Abstract][Full Text] [Related]
34. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys.
Morse BL; MacGuire JG; Marino AM; Zhao Y; Fox M; Zhang Y; Shen H; Griffith Humphreys W; Marathe P; Lai Y
AAPS J; 2017 Nov; 19(6):1878-1889. PubMed ID: 29019117
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
[TBL] [Abstract][Full Text] [Related]
36. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
37. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
[TBL] [Abstract][Full Text] [Related]
38. PBK modelling of topical application and characterisation of the uncertainty of C
Li H; Reynolds J; Sorrell I; Sheffield D; Pendlington R; Cubberley R; Nicol B
Toxicol Appl Pharmacol; 2022 May; 442():115992. PubMed ID: 35346730
[TBL] [Abstract][Full Text] [Related]
39. Extrapolation of the Hepatic Clearance of Drugs in the Absence of Albumin In Vitro to That in the Presence of Albumin In Vivo: Comparative Assessement of 2 Extrapolation Models Based on the Albumin-Mediated Hepatic Uptake Theory and Limitations and Mechanistic Insights.
Poulin P; Haddad S
J Pharm Sci; 2018 Jul; 107(7):1791-1797. PubMed ID: 29567347
[TBL] [Abstract][Full Text] [Related]
40. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
